Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOW-OGESTREL-21 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norgestrel: 18-28 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Hepatic via CYP3A4 isoenzymes (ethinyl estradiol and norgestrel undergo hydroxylation and conjugation). Enterohepatic circulation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Ethinyl estradiol and norgestrel are excreted primarily as glucuronide and sulfate conjugates in urine (50-60%) and feces (30-40%).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norgestrel: 93-95% (albumin, SHBG); ethinyl estradiol: 97-98% (albumin).
~99% bound to serum albumin and sex hormone-binding globulin.
Norgestrel: 3.5-4.5 L/kg; ethinyl estradiol: 2.5-3.5 L/kg; indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: norgestrel >90%; ethinyl estradiol 40-50% (first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
No dosage adjustment required for mild to moderate renal impairment. Use is contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Do not use.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, use same dosing as adults: one tablet daily for 21 days, then 7 days off.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women. No specific geriatric dosing; contraindicated in women over 35 who smoke, and generally avoided in older women due to increased cardiovascular risk.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke). Risk increases with age (>35 years) and smoking severity. Women over 35 who smoke should not use this drug.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thromboembolic disorders (venous and arterial),Cerebrovascular disease,Myocardial infarction,Hypertension,Hepatic adenoma or carcinoma,Gallbladder disease,Carbohydrate/lipid metabolism effects,Ocular changes (e.g., retinal thrombosis),Headache/migraine exacerbation,Uterine bleeding irregularities,Fetal development (discontinue if pregnancy suspected),Depression,Contact lens intolerance,Fluid retention,Breast cancer risk (ongoing surveillance),Hereditary angioedema
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Known or suspected pregnancy,Current or history of thrombophlebitis or thromboembolic disorders,Current or history of cerebrovascular or coronary artery disease,Breast cancer or other estrogen-sensitive neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known liver impairment,Major surgery with prolonged immobilization,Diabetes mellitus with vascular involvement,Uncontrolled hypertension,Hypertriglyceridemia,Smoking >15 cigarettes/day and age ≥35,Migraine with focal aura at any age
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice may slightly increase estrogen exposure but does not require avoidance. Alcohol does not impair contraceptive efficacy but may increase risk of nausea or missed doses.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy category X. Contraindicated in pregnancy. Fetal risk includes cardiovascular anomalies, neural tube defects, and limb reduction defects if exposed during first trimester. Second and third trimester exposure may cause masculinization of female fetuses due to progestin component.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of ethinyl estradiol and norgestrel are excreted in human milk. M/P ratio not established. May reduce milk production and composition. Use is generally not recommended during breastfeeding; alternative contraception advised.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustments indicated as drug should not be used. Pharmacokinetic changes in pregnancy (e.g., increased clearance) are not relevant due to contraindication.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
LOW-OGESTREL-21 is a low-dose estrogen-progestin combination oral contraceptive. Its effectiveness may be reduced by concomitant enzyme-inducing drugs (e.g., rifampin, carbamazepine, phenytoin, St. John's wort). Breakthrough bleeding and spotting are more common with low-dose formulations. Contraception is not reliable if two or more active pills are missed; backup contraception is required. Initiation on the first day of menstrual bleeding eliminates need for backup contraception. Advise patients to take pill at same time daily to maintain consistent hormone levels.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time, even if you have spotting or bleeding between periods.,If you miss one pill, take it as soon as you remember and continue the next pill at the usual time; no backup is needed.,If you miss two consecutive active pills, take two pills daily for two days, then resume one daily; use backup contraception for 7 days.,Possible side effects include nausea, headache, breast tenderness, and irregular bleeding; these often improve after 3 cycles.,Smoking while using this pill increases risk of serious cardiovascular events; do not smoke if over 35 years old.,Use a backup method (e.g., condoms) until you have taken 7 consecutive active pills if starting for the first time after day 5 of menstrual cycle.,Store pills at room temperature away from moisture.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOW-OGESTREL-21 vs AFIRMELLE, answered by our medical review team.
LOW-OGESTREL-21 is a Oral Contraceptive that works by Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOW-OGESTREL-21 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOW-OGESTREL-21 is: One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOW-OGESTREL-21 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOW-OGESTREL-21 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. Fetal risk includes cardiovascular anomalies, neural tube defects, and limb reduction defects if exposed during first trimester.. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.